- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2020 State of the States Medical Cannabis in America Medical Cannabis Access for Pain Treatment
- Join Join
Becoming a Patient in Oklahoma
Any person diagnosed with Lennox-Gastaut Syndrome, Dravet Syndrome or any other severe form of epilepsy that is not adequately treated by traditional medical therapies is eligible to become a patient to be treated by CBD oil which contains no more than 0.3% THC, and which is obtained from a provider approved by the FDA who has manufactured and tested the oil in a facility approved by the FDA.
In addition, any person diagnosed with spasticity due to multiple sclerosis or paraplegia, intractable nausea and vomiting, or appetite stimulation with chronic wasting diseases is exempt from criminal prosecution for possession of CBD oil which contains no more than 0.3% THC.
Qualifying patients are protected from arrest, prosecution or any civil penalty. There is no requirement for state registration. CBD oil used for a clinical trial must be obtained from a provider approved by the FDA who has manufactured and tested the oil in a facility approved by the FDA. The law is silent as to how other patients should obtain CBD oil.
Any of the following:
- Lennox-Gastaut Syndrome
- Dravet Syndrome, also known as Severe Myoclonic Epilepsy of Infancy
- any other severe form of epilepsy that is not adequately treated by traditional medical therapies
- spasticity due to multiple sclerosis or due to paraplegia
- intractable nausea and vomiting
- appetite stimulation with chronic wasting diseases
There is no formal patient registration set forth by the law. Patients must be enrolled in an authorized clinical research program to obtain access to CBD oil as described above.
The law does extend protection to parents, legal guardians or caretakers of patients for the possession CBD oil that has no more than 0.3% THC. The law does not create a production or distribution system.
The law does not impose restrictions on where patients may use their medicine.
There are no age restrictions.
While there are no explicit privacy protections, there is no patient registry under the law.
The law does not provide housing discrimination protection for patients.
The law does not provide employment discrimination protection for patients.
The law is silent on whether insurance would cover CBD oil.
Out of State Patients
The law does not provide legal protections for out of state patients.